Silver Book Fact

The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.

Rein D, Wittenborn J, Zhang X, Honeycutt A, et al. Forecasting Age-Related Macular Degeneration Through the Year 2050. JAMA Ophthalmol. 2009; 127(4): 533-40. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/422785

Reference

Title
Forecasting Age-Related Macular Degeneration Through the Year 2050
Publication
JAMA Ophthalmol
Publication Date
2009
Authors
Rein D, Wittenborn J, Zhang X, Honeycutt A, et al
Volume & Issue
Volume 127, Issue 4
Pages
533-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • Remote Interpretation of Retinal Imaging for DR
    Use of remote interpretation of retinal imaging in diabetics sent via tele-ophthalmology, improved the frequency of screening from 32% to 71% in only 12 months.  
  • Studies of patients with myocardial infarction found that warfarin reduced stroke risk compared to placeboby 40% to 55%.  
  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…  
  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.